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Treatment options for paediatric pulmonary
arterial hypertension
R.M.F. Berger* and D. Bonnet#
ABSTRACT: Pulmonary arterial hypertension (PAH) is a serious, progressive condition, which
can present idiopathically or secondary to conditions such as systemic sclerosis or congenital
heart disease. The condition exists in both adult and paediatric forms, which possess several
similar characteristics. Adult and paediatric PAH can, however, be distinguished based on
underlying pathology and the presence of age-specific conditions, some of which are related to
poor lung development in children. Improved knowledge of vascular biology has led to the
development of several PAH-specific therapies, which have demonstrated clinical benefits in
adults, including improved exercise capacity and prolonged survival. Treatment data in paediatric
PAH are scarce. Although limited, the existing data indicate that current treatments for paediatric
PAH are well tolerated and effective, at least in the short- and medium-term. Nevertheless, the
current guidelines for clinicians, which recommend use of the adult treatment algorithm in
paediatric patients, appear justified when judged according to the available evidence. However,
further randomised, controlled trials are necessary to increase the evidence base for treatment of
paediatric PAH, especially in relation to age-specific conditions. At present, early initiation of
treatment and combination pharmacological therapy may offer the most promising courses of
action to improve outcomes in paediatric PAH.
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T
he characteristics of pulmonary arterial
hypertension (PAH) in the paediatric age
group show both similarities and differ-
ences when compared with PAH in adults. On one
hand, pulmonary vascular pathology in PAH,
including medial hypertrophy, neointimal lesions
and plexiform lesions, is similar in adults and
children, although children have been suggested
to present with more medial hypertrophy [1].
Also, vascular biology in PAH is believed to be
defined by similar patterns of disturbed vascular
and endothelial function in both age groups [2].
Haemodynamic alterations, including increased
pulmonary arterial pressure and resistance, as per
definition of the disease, are present in both
children and adults, and dyspnoea at exertion is
the most common clinical symptom in both
populations [3, 4]. Heart failure with oedema
seems to be less frequent in children, whereas
syncope occurs more frequently in children with
idiopathic PAH (IPAH) [3–5].
On the other hand, the distribution of underlying
conditions in PAH differs between paediatric and
adult populations. In children, PAH is associated
with congenital heart disease (CHD) in 40–50% of
patients, with diagnoses of IPAH or familial
PAH, now reclassified as heritable PAH (HPAH),
being present in virtually all of the remainder [4,
6]. In addition, the types of CHD that occur in
children in association with PAH are more
heterogeneous than those observed in adults.
PAH associated with connective tissue disease
(CTD), HIV, portal hypertension or drugs/toxins
do occur in children, but are extremely rare [4,
6].This is in contrast to adults with PAH, in
whom an association with CHD accounts for 11–
20% of the population and IPAH/HPAH, CTD-,
anorexigen-, portal hypertension- and HIV-asso-
ciated PAH account for 43%, 15%, 10%, 10% and
6%, respectively [7].
As childhood PAH is most commonly associated
with CHD, the majority of paediatric PAH patients
are managed by paediatric cardiologists. In young
children with CHD and unrestrictive shunts,
where pulmonary blood flow is increased and
pulmonary arterial pressure is elevated but pul-
monary vascular resistance is low or mildly ele-
vated, there exists early and reversible pulmonary
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vascular disease. It is obvious that, in these patients, treatment of
choice is surgical repair of the heart defect in order to normalise
pulmonary arterial pressure, rather than treatment with PAH
drugs. In other words, before embarking on pharmacotherapy,
the first step in the treatment of children with CHD and
pulmonary hypertension should be to assess the progression of
pulmonary vascular disease and the possibility of surgical
correction [8]. Conversely, patients with CHD associated with
a left-to-right shunt, whose pulmonary vascular disease has
already progressed to an advanced, irreversible stage, should not
be considered for closure of the heart defect. In these patients,
PAH may persist postoperatively and outcome may be worse
than in patients with unrepaired PAH-CHD or Eisenmenger’s
syndrome [9]. It is these latter groups of PAH-CHD patients
for whom PAH drug treatment options are applicable, and
which are discussed in the current paper. Childhood PAH often
presents with several unique, age-specific conditions, includ-
ing bronchopulmonary dysplasia or congenital diaphragmatic
hernia, both associated with disordered lung development. At
present, the role of these conditions in pulmonary hypertension
is poorly defined. Paediatric PAH has been frequently associated
with chromosomal or syndromal abnormalities, most frequently
trisomy 21, and with complex diagnosis due to multiple
underlying conditions [4]. Persistent pulmonary hypertension
of the newborn (PPHN), which occurs exclusively in the
neonatal period, is also classified as PAH according to the
Dana Point clinical classification of pulmonary hypertension
[10]. However, the epidemiology, natural history, treatment and
outcome of PPHN are sufficiently distinct from the chronic,
progressive PAH seen in paediatric patients that we have
excluded it from the present discussion [11]. Finally, untreated
paediatric PAH has been reported to be associated with a
median survival of 10 months, which is worse compared with
adults (median untreated survival of 2.8 yrs) [12]. However,
these unfavourable survival times for paediatric PAH have been
challenged by recent data [5, 13].
In recent decades, increased knowledge of pulmonary vascular
biology has led to novel therapies for PAH, which have
demonstrated beneficial effects including increased exercise
capacity, improved quality of life and prolonged survival.
These effects have been demonstrated mainly in adults with
PAH. Evidence-based treatment guidelines have subsequently
been developed, based on continuously growing evidence
derived from multiple clinical trials in adult PAH patients [14].
In contrast, very limited controlled data exist that report
treatment responses in paediatric PAH.
In view of the foregoing considerations, the question arises as
to whether paediatric and adult PAH should be treated
according to the same treatment algorithms. The current
guidelines recommend consideration of the same therapeutic
algorithm for adults and children (fig. 1) [14]. This proposal is
a class IIa recommendation (‘‘the weight of evidence/opinion
is in favour of usefulness/efficacy’’), based on level of
evidence C (‘‘a consensus of opinion of the experts and/or
small or retrospective studies [or] registries’’) [14].
In this paper, we will discuss the treatment algorithm for adult
PAH as proposed by current guidelines, and summarise the
available data concerning its use in paediatric PAH.
GENERAL MEASURES AND SUPPORTIVE THERAPIES
The general measures and supportive therapies proposed in
the guidelines are mostly supported by class IIa recommenda-
tions (weight of opinion in favour of efficacy), based on level of
evidence C (consensus of expert opinion). The situation is
similar for paediatric PAH [14].
Oxygen administration
One report on oxygen administration (.12 h?day-1) in children
with PAH, mainly PAH-CHD, suggested a beneficial effect on
survival [15], whereas no beneficial effects of nocturnal oxygen
administration could be demonstrated in adult patients with PAH-
CHD [16]. In general, an improved level of subjective well-being
experienced by a subgroup of patients with some degree of
hypoxaemia may be the main indication for oxygen administration.
Anticoagulant therapy
The use of anticoagulant therapy in PAH is based on the
concept of a prothrombotic microenvironment and the finding
of (micro)thrombi in the pulmonary vasculature of patients
with PAH, and is supported by observational data from adults
with mainly IPAH/HPAH [17, 18]. However, the potential
benefits of oral anticoagulant therapy should be weighed
against risks in specific patient groups, such as, for example,
haemoptysis and a general bleeding tendency in patients with
Eisenmenger’s syndrome [19–21]. The use of anticoagulant
therapy in children with PAH is increasingly recommended,
especially in conditions such as hypercoagulability, and overt
heart failure, and where there is an indwelling central venous
line, although no data are available on the efficacy and risk/
benefit ratio of oral anticoagulation in children with PAH [18,
22]. Anticoagulant therapy in young children may be accom-
panied by age-specific problems of administration, response
and dosing [23]. Therapy with anticoagulants should, there-
fore, be considered on an individual patient basis.
Infection prevention
Although no controlled data exist, vaccination against influ-
enza and pneumococcal disease is recommended in PAH
patients [14]. In children, additional infection prevention in
specific age groups should be considered, such as respiratory
syncytial virus prophylaxis in infants with PAH [24, 25].
CALCIUM-CHANNEL BLOCKERS
Uncontrolled, open-label, prospective, observational studies
have reported improved haemodynamics and survival with
long-term calcium-channel blocker therapy in both adult and
paediatric patients with IPAH/HPAH, provided they
responded to acute vasodilator testing at initiation of therapy
[26, 27]. Unfortunately, however, acute responders comprise less
than 10% of adult patients with IPAH. In children, the
proportion of acute responders has been suggested to be higher,
although this difference may be due to disparate criteria used to
identify responders. The ‘‘Sitbon criteria’’ for acute responders in
adult IPAH, now generally used, have not been studied in
paediatric PAH [28]. Vigilance is necessary, since a significant
number of patients lose their initial responsiveness, sometimes
within 1 yr, a situation that precedes deterioration of disease. In
these patients, the treatment strategy must be adapted to include
specific, PAH-targeted therapy, as is the case with PAH patients
who showed no acute, initial response to vasodilator testing.
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PROSTANOIDS
Prostacyclinisanendogenous,potentpulmonaryandsystemicvaso-
dilator, with antimitogenic properties and antiplatelet activity.
Reduced expression of prostacyclin synthetase in pulmonary endo-
thelium and an imbalance between the thromboxane and prostacy-
clin metabolites have been observed in patients with PAH [29, 30].
Epoprostenol
The prostacyclin analogue epoprostenol has a very short half-
life of 3–6 min, and so must be administered continuously
through a permanent intravenous catheter. Its use is recom-
mended as first-line treatment in patients with severe PAH in
World Health Organization (WHO) functional class (FC) IV
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FIGURE 1. Evidence based-algorithm for patients with pulmonary arterial hypertension (PAH). IPAH: idiopathic PAH; APAH: associated PAH; WHO FC: World Health
Organization functional class; CCB: calcium-channel blocker; ERA: endothelin-receptor antagonist; PDE-5i: phosphodiesterase type-5 inhibitor; BAS: balloon atrial
septostomy. #: to maintain arterial blood O2 pressure o8 kPa (60 mmHg);
": under regulatory review in the European Union; +: IIa-C for WHO FC II. Reproduced from [14]
with permission from the publisher.
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(level of evidence A) (fig. 1) [14]. This indication is similar in
adults and children with IPAH, and is based on observational
data showing continuous i.v. epoprostenol to be equally
effective in children and adults for improving symptoms,
haemodynamics and survival [27, 31]. LAMMERS et al. [32]
recently confirmed these data in children with IPAH, and
demonstrated similar results in children with PAH-CHD
treated with i.v. epoprostenol.
The long-term persistence of these beneficial effects, as reported
by YUNG et al. [33], who showed a 10-yr survival of 61% in IPAH
patients, indicates that the use of epoprostenol in children is
justified despite the invasive nature of its delivery system and
its risk for associated complications, such as thromboembolic
events, line sepsis, local infection or catheter displacement. In
patients with PAH-CHD and right-to-left shunting, the addi-
tional risks of such complications, which also include cerebral
emboli or abscesses, must be weighed against the expected
therapeutic benefits on an individual basis.
Side-effects of epoprostenol, which include facial flushing,
headache, nausea, jaw pain, abdominal cramping and diar-
rhoea, are transient, occur at similar rates in children and
adults and are often related to initiation of therapy or dose
increments. Clinical observations from centres experienced in
the treatment of both adult and paediatric PAH patients
suggest that optimal dosing in children is higher than in
adults, although objective supporting data are missing. More
stable analogues of prostacyclin have been developed that
allow for less invasive routes of administration. Clinical
efficacy of these analogues has been demonstrated in adults,
whether administered intravenously (iloprost, treprostinil),
subcutaneously (treprostinil), by inhalation (iloprost, trepros-
tinil) or orally (beraprost), and these agents are recommended
with varying levels of evidence for patients in WHO FC III
(fig. 1) [14]. However, data on the use of these analogues in
children are scarce.
Treprostinil
Treprostinil sodium, a prostacyclin analogue with an elimina-
tion half-life of 4–5 h, allows for i.v. or s.c. administration [34]
or inhalation [35]. Several studies that included both older
children and adults demonstrated or suggested efficacy of
treprostinil i.v. or s.c. in different forms of PAH [36–38].
However, the proportions of children included in these studies
were very small (,5%), and the paediatric results were not
analysed separately. Side-effects, in addition to the prostanoid-
specific facial flushing, headache, jaw pain and diarrhoea, are
dominated by pain at the subcutaneous infusion site. This
clinically important side-effect has largely precluded its use in
children.
Recently, small, uncontrolled reports provide preliminary
evidence that selected children with PAH can safely be
switched to s.c. treprostinil from oral therapy in case of clinical
deterioration [39], or as an alternative to IV epoprostenol [40].
Recently, add-on therapy with inhaled treprostinil in adult
PAH patients already using either bosentan or sildenafil was
shown to be effective [41], but no paediatric data are available.
Finally, treprostinil for oral administration, an attractive option
for children, is under development.
Iloprost
Iloprost is a stable analogue of prostacyclin with a biological
half-life of 20–30 min [42]. The use of i.v. iloprost, although
widespread in some countries, has never been studied in a
randomised, controlled trial. Inhaled iloprost has been demon-
strated to improve functional class and 6-min walk distance in
adult patients with PAH or inoperable chronic thromboembolic
pulmonary hypertension [43]. However, haemodynamics were
improved only when measured directly after inhalation, while
trough values after 12 weeks were similar to baseline. Patients
have to inhale the drug not less than six to nine times per day,
which poses practical limitations, especially in children.
Data in children are limited. Recently, IVY et al. [44] reported
safety and efficacy data in paediatric patients with PAH.
Inhaled iloprost caused sustained functional improvement in
some children with PAH, and patients could be transitioned
from i.v. to inhaled prostanoid therapy. However, inhaled
iloprost occasionally induced bronchoconstriction. The authors
concluded that clinical deterioration, side-effects and poor
compliance owing to the frequency of administration could
limit chronic treatment in children [44]. Additionally, inhaled
iloprost was shown to be equally effective as inhaled nitric
oxide for lowering mean pulmonary artery pressure and
pulmonary vascular resistance index, which may indicate a use
for these acute haemodynamic effects of inhaled iloprost in a
critical care setting.
Oral beraprost
Beraprost sodium is a stable prostacyclin analogue with a half-
life of 1–2 h, which allows for oral administration. Two
randomised, controlled studies with beraprost have shown
improvement of exercise capacity in adults with PAH after
3 months and 6 months, but not at either 9 months or
12 months [45, 46]. Therefore, the use of beraprost in PAH is
no longer recommended by most experts. Adequate data
concerning the clinical effect of beraprost in children with PAH
are not available.
ENDOTHELIN-RECEPTOR ANTAGONISTS
The endothelin (ET) system is activated in the different forms
of PAH. ET-1 is a potent endogenous vasoconstrictor with
mitogenic properties that it exerts through two receptor
subtypes: ETA receptors are localised to vascular smooth
muscle cells and fibroblasts, whereas ETB receptors are
predominantly localised to pulmonary endothelial cells and,
to a lesser extent, vascular smooth muscle cells. The ETB
receptors are involved in ET-1 clearance, and activation
induces the release of vasodilatory and antiproliferative
substances, such as nitric oxide. Dimerisation theory suggests
that ETB receptors expressed on vascular smooth muscle cells
have the ability to couple with ETA receptors, and may
subsequently adopt the function of the latter and mediate
vasoconstriction [47]. Despite the differences in receptor
isoform activity, both dual ETA-/ETB-receptor antagonists
(bosentan) and selective ETA-receptor antagonists (sitasextan
and ambrisentan) have demonstrated similar effectiveness in
adult patients with PAH, improving haemodynamics, exercise
capacity and WHO FC. ET-receptor antagonists (ERAs) are
recommended as potential first-line treatment for WHO FC II/
III PAH patients, with evidence mostly at level A. Their use in
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FC IV PAH patients is supported by a class IIa recommenda-
tion, level of evidence C (fig. 1) [14].
Bosentan
Bosentan is an oral, dual ERA that has been demonstrated to
improve haemodynamics, exercise capacity, time to clinical
worsening and WHO FC in adults with PAH [48–50] and
haemodynamics, exercise capacity and WHO FC in those with
Eisenmenger’s physiology [51, 52].
Although no randomised, controlled trial has yet been
performed in children with PAH, open-label controlled and
uncontrolled studies in children demonstrate improvements in
haemodynamic measurements, exercise capacity or WHO FC
with bosentan therapy, either as monotherapy or in combina-
tion with other PAH therapies [53–57]. Pharmacokinetics,
safety and efficacy of bosentan in paediatric patients have also
been studied, the results demonstrating lower bosentan
exposure in paediatric patients compared to adult patients,
despite increased doses [53, 54]. Bosentan was well tolerated
and improved pulmonary haemodynamics after 12 weeks.
ROSENZWEIG et al. [55] described the long-term outcome of
children with PAH treated with bosentan, with or without
concomitant prostanoid therapy. Their results suggested
improvement in pulmonary haemodynamics after a mean
follow-up of 9 months, with 1- and 2-yr survival rates of 98%
and 91%, respectively. In an open-label study, VAN LOON et al.
[57] compared the effects of bosentan in 10 children versus 20
adults with PAH associated with systemic-to-pulmonary
shunts, who were predominantly on bosentan monotherapy.
Their data indicated that the initial improvement in exercise
capacity in both adults and children progressively declined at
longer-term follow-up, a deterioration that was more pro-
nounced in the paediatric patients.
Current data suggest that the safety profile of bosentan is
comparable between adults and children, with the type and
incidence of reported side-effects being similar [6, 54]. The
potential exception is elevated transaminase levels, which occur
in children but less frequently than in adults (2.7% versus 7.8%,
respectively), according to the European bosentan postmarket-
ing surveillance programme [6]. Recently, a paediatric disper-
sible tablet formulation of bosentan has become available in the
European Union (EU) only for children .2 yrs of age, allowing
further optimisation of the dose for young children [54].
Sitaxentan
Sitaxentan, an oral, highly selective ETA-receptor antagonist
approved for use in the EU, Canada and Australia, has been
demonstrated to improve exercise capacity and haemody-
namics in patients older than 16 yrs of age with PAH, including
IPAH, PAH-CTD and PAH-CHD [58, 59]. An open-label study
has demonstrated the persistence of this effect over time [60].
However, no specified data from the limited subgroup of
patients with PAH-CHD in these studies have been published.
Data in younger children are very limited [61].
Ambrisentan
Ambrisentan, an oral, selective ETA-receptor antagonist, has been
demonstrated to improve exercise capacity, haemodynamics
and time to clinical worsening in adults with PAH [62, 63].
Ambrisentan is well tolerated and associated with an apparent
lower risk of transaminase elevation and suggested to have a
lower drug interaction than other agents in the same class [14].
A controlled, open-label study investigating pharmacokinetics,
tolerability, safety and efficacy of ambrisentan in paediatric
PAH has been initiated, but no data are currently available.
PHOSPHODIESTERASE-5 INHIBITORS
Inhibition of phosphodiesterase type 5 (PDE5) induces
vasodilation through the nitric oxide/cyclic guanosine mono-
phosphate pathway, and also exerts antiproliferative effects
[64, 65]. Inhibitors of PDE5, such as sildenafil or tadalafil, have
been evaluated in adults with PAH, and were demonstrated to
improve haemodynamics, exercise capacity and WHO FC in
patients with IPAH, PAH-CTD or PAH-CHD after 12 weeks of
treatment [66, 67]. Sildenafil and tadalafil are recommended
for first-line treatment of patients with PAH, supported by
levels of evidence A and B, respectively (fig. 1) [14].
Sildenafil
Open-label observational studies in children with various
types of progressive PAH suggest a similar effect of sildenafil
on haemodynamics and exercise capacity at 1-yr follow-up
[68]. Sildenafil therapy was well tolerated and no significant
adverse effects were observed. Data recently presented at the
2009 European Respiratory Society congress from a rando-
mised, placebo-controlled, dose-ranging study confirm the
safety and tolerability of sildenafil therapy in paediatric
patients with IPAH/HPAH and PAH-CHD [69]. Furthermore
a near-significant trend was observed for the increase in
maximal oxygen uptake in a subgroup of patients that could
perform a reliable exercise test. These data, which are yet to be
published in full, generally support the efficacy of sildenafil in
paediatric PAH.
In a critical care setting, sildenafil has been demonstrated to be
an equally effective pulmonary vasodilator as inhaled nitric
oxide, with potential application to augment the pulmonary
vasodilatory action of nitric oxide inhalation and to facilitate
nitric oxide withdrawal. However, these effects came at the
potential cost of systemic hypotension, increased pulmonary
shunting and impaired oxygenation [70, 71].
An intravenous form of sildenafil has recently been approved
for use in the USA and EU, the obvious application of which is
in situations where enteral use is not possible.
Tadalafil
Tadalafil is a selective PDE5 inhibitor that can be administered
once daily. Its beneficial effects in PAH, consisting of improved
exercise capacity, haemodynamics and time to clinical worsen-
ing, have been demonstrated in adults [67]. However, data in
children are not available.
COMBINATION THERAPY
Available data on the previously described, targeted PAH
therapies suggest that they are generally effective, well
tolerated and safe in both children and adults. These therapies
target different pathways involved in the pathophysiology of
PAH. Combination therapy is an attractive concept, as by
acting on multiple pathways simultaneously, they may be
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more effective than targeting just one pathway. The treatment
algorithm recommends combination therapy, however, with-
out specifying which combination should be used (class IIa
recommendation/level of evidence B) (fig. 1) [14].
Data are available from adult patients on the additional value
of combining targeted PAH treatments, mostly relating to add-
on therapy. For example, bosentan added to i.v. epoprostenol
background therapy [72], sildenafil added to i.v. epoprostenol
[73] and inhaled treprostinil added to either bosentan [41, 74]
or sildenafil [41] have been studied, with the results indicating
additional beneficial effects for the combination.
The optimal timing of combination therapy remains unclear,
but HOEPER et al. [75] developed a treatment algorithm based
on the concept of ‘‘goal-oriented treatment’’. Applying their
goal-oriented treatment algorithm to the decision-making of
the authors [75] led to improved survival in their centre.
Whether or not these results are applicable to infants and
children with PAH remains unclear. Recently published data
on paediatric PAH in the current era of targeted PAH
treatments demonstrated improved survival with these
therapies, compared with predicted survival values [13].
However, this improvement appeared to be driven by
patients who were diagnosed before the new therapies were
available, while improved survival was not achieved in newly
diagnosed children (fig. 2) [13]. These findings suggest that
optimisation of therapy is required, possibly through more
aggressive therapy and earlier initiation of combination
therapy.
FUTURE PHARMACOLOGICAL TREATMENT OPTIONS
Recent developments in vasodilatory and antiproliferative
approaches for the treatment of PAH have led to the ongoing
clinical evaluation of new pharmacological compounds, with
promising, albeit preliminary, results. These compounds
include soluble guanylate cyclase agonists, platelet-derived
growth factor-receptor antagonists, prostacyclin-receptor ago-
nists and tyrosine kinase inhibitors. Clinical studies of these
compounds are underway in adult patients with PAH. No data
in paediatric PAH are available, but these compounds are
expected to play a future role in paediatric PAH.
NONPHARMACOLOGICAL THERAPIES
According to the current treatment algorithm, atrial septost-
omy and/or lung transplantation should be considered in
patients with inadequate response to maximal pharmacologi-
cal therapy (level of evidence C) (fig. 1) [14].
Atrial septostomy may decompress the right heart and improve
systemic cardiac output, albeit at the cost of hypoxaemia, and
has been shown to relieve symptoms in a paediatric case series
[76]. Patients with persistent syncope or with intractable right
heart failure may benefit from this intervention. The procedure
can be used as a bridge to lung transplantation. However, the
effect of the procedure may be unpredictable, and its mortality
is substantial (5–15%) and seems to increase in patients with
high right atrial pressures. The surgical creation of a Potts’
shunt has been suggested as an alternative approach in patients
with suprasystemic pulmonary vascular resistance [77].
However, the risk–benefit ratio of these procedures has not
yet been established and optimal timing remains extremely
difficult. For these reasons, they should only be conducted by
centres with considerable experience of performing such
procedures in children with PAH.
The decision to schedule a patient for lung (or heart–lung)
transplantation should be based upon an assessment of pro-
gnosis, local donor availability and, thus, waiting time for
transplantation and, finally, expected survival after transplan-
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FIGURE 2. Observed survival (–––––) with 95% confidence intervals (? ? ? ? ?)
and predicted survival using the National Institutes of Health registry equation
(– – – – ) from time of second-generation drug availability in a) patients for whom
pulmonary arterial hypertension (PAH)-specific drugs became available during or
before their diagnoses (n545), b) patients for whom PAH-specific drugs were
not available at time of diagnosis but became available during the disease
course (n521) and c) patients for whom second-generation drugs were available
at time of diagnosis (n524). Reproduced from [13] with permission from the
publisher.
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is 4.3 yrs, with a tendency toward improved outcome in
younger children (0–10 yrs). The 3- and 5-yr survival rates in
children with heart–lung transplantation are 69% and 45%,
respectively [78].
TREATMENT GOALS IN PAEDIATRIC PAH
The response to treatment can be difficult to quantify in
children. Additionally, it can be challenging to perform and
interpret the traditional endpoints used in trials with adults
such as the 6-min walk test, functional class and quality of life.
The composite end-point of time to clinical worsening is
gaining acceptance as a better indicator of clinical status and
disease progression. However, this indicator needs a clear
definition that may differ according to age or PAH aetiology in
the paediatric population. The effectiveness of PAH therapies
is increasingly being assessed through goal-oriented strategies
in adult trials [75]. This seductive approach in which goals of
treatment and follow-up procedures are predefined has not
been applied to children but it could be used to tailor PAH
therapy to individual patients. As proposed in the recent
guidelines, regular evaluation of children with PAH should
focus on variables with prognostic significance and treatment
decisions should be based on parameters that are relevant for
outcome [14]. In daily practice, clinical evaluation, exercise
tests, biochemical markers, such as the N-terminal prohor-
mone of brain natriuretic peptide, and echocardiographic
assessments are required to have a clear picture of a child’s
condition [79]. It is also of note that decision making does not
rely on a single parameter but on either their convergent or
divergent results. Interpreting this composite information to
guide therapy is a daily challenge in the management of
children with PAH.
CONCLUSIONS
Despite several similarities, paediatric PAH has a distinct
presentation compared with adult PAH. Not only are the
conditions underlying PAH different in adults and children,
with CHD far more predominant among paediatric patients,
but the two populations are further distinguished by the
presence of age-specific conditions that may be related to
impaired lung development in children, including bronch-
opulmonary dysplasia or congenital diaphragmatic hernia.
It becomes obvious, therefore, that paediatric PAH is a
complex presentation that occurs among a heterogeneous
group of patients and requires an extensive clinical work-up
in order to appropriately define the aetiology in individual
cases.
Examination of the current literature reveals limited data
concerning the effect of treatments in paediatric PAH, for both
general therapies and those specific to the disease. However,
those data that are available suggest that, in the short- to
medium-term at least, treatment effects in children are
comparable to those observed in adults.
The majority of prostanoid data is derived from studies of
epoprostenol. In current guidelines this compound is recom-
mended as a first-line treatment for patients with severe PAH
(WHO FC IV) [14] and the literature confirms that paediatric
use of epoprostenol is justified by its long-term functional and
survival benefits, despite problems with continuous i.v.
infusion. Recommendation of treprostinil is limited in
children because of a lack of data and side-effects that include
infusion site pain, although it may prove to be a useful switch
therapy in cases of clinical deterioration or when an
alternative to epoprostenol is required. The utility of inhaled
iloprost in children is similarly limited by side-effects, but
also by an inconvenient dosing schedule, but it may offer an
alternative treatment option in selected paediatric cases.
Insufficient data exist concerning oral beraprost in children,
a situation that is unlikely to change given its low standing
among experts. Of the ERAs, bosentan has been the most
studied in the paediatric setting. Open-label studies in
children have confirmed the positive efficacy and safety
findings observed in adults, while demonstrating lower
bosentan exposure in children in spite of increased doses.
Uncontrolled data suggest that bosentan improves haemody-
namic measures in children at short- and mid-term follow-up.
However, data on longer term follow-up in children are more
ambiguous and long-term deterioration of initial improve-
ment in exercise capacity may be more prevalent in paediatric
patients on monotherapy than in adults. A lack of data makes
it difficult to assess the paediatric situation with regard to
sitaxentan and ambrisentan.
In terms of the PDE5 inhibitors, only sildenafil has any
paediatric data available. Open-label observational studies and
preliminary results of a randomised, controlled trial appear to
confirm the efficacy, safety and tolerability of sildenafil in
paediatric patients with various forms of PAH.
According to current clinical guidelines, the adult PAH
treatment algorithm should also be followed in paediatric
patients, although this advice is a class IIa ‘‘weight of
evidence’’ recommendation based on grade C ‘‘consensus of
opinion’’ evidence [14]. Review of published data and current
paediatric expert opinions support that advice; however, in
order to provide clinicians with more robust recommendations
based on firm experimental evidence, randomised, controlled
clinical trials of PAH treatments in the paediatric setting are
necessary. In particular, although not exclusively, safety
studies, pharmacokinetic investigations and studies of treat-
ment in PAH patients with age-specific conditions, including
bronchopulmonary dysplasia, congenital diaphragmatic her-
nia or trisomy 21, would provide a useful widening of the
evidence base in paediatric PAH.
Due to its progressive and devastating nature, the pro-
gnosis of paediatric PAH remains a serious concern. A
plethora of pharmaceutical treatments options are on the
horizon, which may offer increased hope in the future; but
until then, timely treatment and early combination therapy
may be the best courses of action to improve survival in
childhood PAH.
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